Internal Medicine Grand Rounds: New Anti-Clotting Drug

Internal Medicine Grand Rounds: New Anti-Clotting Drug

Feb 4, 2011 1:34 PM

(SALT LAKE CITY)—For the first time in more than 50 years, the U.S. Food and Drug Administration has approved a new oral anticoagulant drug, one that potentially can replace the use of Coumadin (warfarin) for many heart and stroke patients. The new drug, Dabigatran (Pradaxa®), can eliminate the need for regular lab testing and dietary restrictions that accompany Coumadin therapy. Yet, challenges are emerging, including the management of urgent medical events such as acute bleeding, emergency surgery, and overdose.

On Thursday, Feb. 10, U of U thrombosis service physicians Robert C. Pendleton, M.D., associate professor of internal medicine, and Matthew T. Rondina, M.D., assistant professor of internal medicine, will give an overview of this major change in anticoagulant therapy and its implications for patient treatment.

Clinicians are encouraged to attend the Department of Internal Medicine Grand Rounds presentation, which takes place from 7:45-8:45 a.m. in room 1730 in the Health Sciences Education Building (HSEB) on the U of U Health Sciences campus. (The address is 26 S. 2000 East, south of University of Utah Hospital and directly across from the College of Pharmacy).

Those who could not attend the grand rounds presentation can view a video of the discussion at .

Physicians who want CME credit for viewing the video should go through the Internal Medicine Grand Rounds page at and click the link “View Video for CME Credit”. Any questions about obtaining CME credit should be directed to Karen James (, 801-581-7606).

Patients are encouraged to learn about the new medication by visiting University of Utah Health Care Thrombosis Service.

# # #

Media Contacts

Phil Sahm
Office of Public Affairs
Phone: 801-581-2517

Visit our News Archive for a complete list of previous News.